SCHEMBL31332945

SCHEMBL31332945

CCOC(=O)c1nc(Cl)cn1CC

nearest known ligand 0.65

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NPC1 O15118 4/20 0.42
KDM4E B2RXH2 3/20 0.42
RAB9A P51151 3/20 0.42
CYP1A2 P05177 2/20 0.41
GABRA2 P47869 2/20 0.41
GABRB2 P47870 2/20 0.41
BAZ2B Q9UIF8 1/20 0.40
BAZ2A Q9UIF9 1/20 0.40
KMT2A Q03164 1/20 0.40
L3MBTL1 Q9Y468 1/20 0.39
SMN1; SMN2 Q16637 2/20 0.39
TDP1 Q9NUW8 1/20 0.39
GAA P10253 1/20 0.38
CYP2C9 P11712 1/20 0.38
CYP2C19 P33261 1/20 0.38
ALDH1A1 P00352 3/20 0.38
POLB P06746 2/20 0.38
TP53 P04637 1/20 0.38
MAPT P10636 1/20 0.38
XBP1 P17861 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL23214261 0.81 LMNA (0.42) NPC1KDM4ERAB9ACYP1A2GABRA2
SCHEMBL1856217 0.80 DGAT1 (0.44) NPC1KDM4ERAB9ACYP1A2GABRA2
SCHEMBL1594228 0.76 ALDH1A1 (0.59) NPC1RAB9AKMT2AL3MBTL1GAA
SCHEMBL13931997 0.75 GABRA2 (0.47) NPC1KDM4ERAB9ACYP1A2GABRA2
SCHEMBL2617373 0.73 HTT (0.51) NPC1KDM4ERAB9ACYP1A2GABRA2
SCHEMBL22858026 0.72 ABCB1 (0.38) NPC1KDM4ERAB9ACYP1A2GABRA2
SCHEMBL12706154 0.70 LPO (0.42) KDM4ECYP1A2KMT2AALDH1A1MAPT
SCHEMBL28223263 0.69
SCHEMBL29339719 0.69 ALDH1A1 (0.53) NPC1KDM4ERAB9AKMT2AL3MBTL1
SCHEMBL18861936 0.69 ADORA3 (0.43) NPC1KDM4ERAB9ACYP1A2KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4709374-A2 KCC2 POTENTIATORS AND USES THEREOF Axonis Therapeutics, Inc. (US) 2026-03-18 EP disclosed
US-20260062402-A1 KCC2 POTENTIATORS AND USES THEREOF AXONIS THERAPEUTICS INC (US) 2026-03-05 US disclosed
WO-2024233885-A2 KCC2 POTENTIATORS AND USES THEREOF AXONIS THERAPEUTICS, INC. (US) 2024-11-14 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20260062402-A1 KCC2 POTENTIATORS AND USES THEREOF HCN2, HCN1, HCN4 NPC1 185/4885KDM4E 2478/4885RAB9A 1666/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.